Navigation Links
GenVec Forms Collaboration With World-Leading Animal Health Company
Date:12/29/2010

GAITHERSBURG, Md., Dec. 29, 2010 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC) today announced that the company will be working with Merial to develop and commercialize GenVec's proprietary vaccine technology for use against foot-and-mouth disease (FMD). Merial is the leading FMD vaccine producer in the world, with leading positions in all key markets. Under the agreement, Merial will be responsible for all costs related to the development and commercialization of FMD vaccines developed through the collaboration.  GenVec will receive development milestones and royalties on sales.  

GenVec's novel FMD vaccine approach utilizes GenVec's proprietary adenovector technology and is manufactured on a proprietary GenVec cell line that is capable of producing antigens without the use of the highly contagious FMD virus. Because the vaccine is produced without using live or killed virus materials, it can be produced cost effectively in the US and around the world.

"We look forward to working with GenVec to explore this promising technology for FMD vaccines," said Teshome Mebatsion, Senior Director Vector Vaccine Research, Merial.  Robert Nordgren, Global Head of Merial's Bio R&D added that "Merial sees great potential for GenVec's technology to positively impact the way that animal vaccines are produced and developed."

"Our relationship with Merial complements our strategy of entering into collaborations to support the development of our pipeline of products," said Dr. Paul Fischer, GenVec's President and Chief Executive Officer.

About GenVecGenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec uses proprietary drug discovery and development technologies to support a portfolio of product programs that address the prevention and treatment of a number of major diseases.  In collaboration with Novartis, GenVec is developing novel treatments for hearing loss and balance disorders. GenVec also develops and is evaluating the potential of TNFerade for the treatment of certain cancers and is developing vaccines for infectious diseases including influenza, HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

About MerialMerial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs approximately 5,600 people and operates in more than 150 countries worldwide. Its 2009 sales were $2.6 billion. Merial is the Animal Health subsidiary of sanofi-aventis.

For more information, please see www.merial.com.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act.  GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.  Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations.  Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.  These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.Investor Contact: GenVec, Inc.Douglas J. Swirsky(240) 632-5510dswirsky@genvec.com
'/>"/>

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GenVec Reports Third Quarter 2010 Financial Results
2. GenVec Receives Second-Year Funding From SAIC for HIV and Influenza Vaccine Development
3. GenVec Receives National Cancer Institute Grant to Expand Cancer Program
4. GenVec Announces Multiple Presentations at the American Society of Tropical Medicine and Hygiene Meeting
5. Cannabis Science Forms Military Advisory Board That Will Be Comprised of Distinguished Military Leaders, Military Health Care Providers, Researchers and Educators Headed Up by Lieutenant Colonel, U.S. Army (Ret) Kevin Sullivan
6. Amylin Submits Clinical and Nonclinical Sections of Rolling Biologics License Application for Metreleptin to Treat Rare Forms of Lipodystrophy
7. Cymetrix Forms Alliance With Siemens Healthcare for System Conversion Support
8. Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates
9. RoundTable Healthcare Partners Portfolio Company, Argon Medical Devices, Inc., Acquires Critical Care and Extended Dwell Catheter Product Platforms From BD
10. Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System
11. Tunnell Consulting Forms Strategic Alliance With Ireland-Based Campbell Informatics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... NORTH READING, Mass. , Dec. 7, 2016 ... Track and Trace Network for connecting the Life ... from the global marketplace, today announced that Tjoapack ... 50+ European pharmaceutical manufacturing customers comply with the ... Supply Chain Security Act (DSCSA) in 2017 and ...
(Date:12/7/2016)... 7, 2016  Varian Medical Systems (NYSE: ... announced plans to separate its Imaging Components business.  The ... distribution to Varian stockholders of common stock in Varex ... hold the Imaging Components business.  As part of the ... the end of January 2017, Varian will receive an ...
(Date:12/7/2016)... 7, 2016  Organovo Holdings, Inc. (NASDAQ: ... focused on delivering scientific and medical breakthroughs using ... and Chief Executive Officer Keith Murphy ... December 14, 2016 at 1:00 p.m. Eastern Time ... yet familiar with the Company, an informational video ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Texas Premier Locksmith ... carried out by unethical locksmith companies and is urging Search Engines to improve ... to Texas Premier Locksmith, these fraudulent locksmith services take advantage of consumers locked ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... "ProBrand Flip ... and all media," said Christina Austin - CEO of Pixel Film Studios. , ProBrand ... easy to use drop zones. Editors can select from a variety of flip book ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... Infertility and Wellness (IFW) Program at Reproductive Medicine Associates of Connecticut (RMACT). McLaughlin ... has a team of three acupuncturists to help patients realize their family building ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Walking With God: Inspirational ... that will inspire the reader to be aware of God's direction in their lives. ... author, Sanford Smith, retired teacher and active church leader. , Sanford says, ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... annual Business Architecture Innovation Summit in Reston, VA on March 21-22, 2017. This ... share a range of experiences from a cross-section of industries such as financial ...
Breaking Medicine News(10 mins):